Skip to main content

Table 3 Standardized dataset for the cost-effectiveness models in rotavirus vaccination: vaccine characteristics (Sources: [1–5, 7, 15, 20, 28], expert opinions)

From: Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world

 

Afr

Sear

Amr

Eur

Notes

Efficacy, assuming a 2-dose schedule at 2 & 3 months (1 dose only between brackets)

     

   Mild

52% (52%)

52% (52%)

52% (52%)

87% (87%)

 

   Moderate

55% (54%)

55% (54%)

55% (54%)

92% (90%)

 

   Severe

60% (54%)

60% (54%)

60% (54%)

100% (90%)

 

Waning of efficacy (annual)

     

   Mild & moderate

0.63

0.63

0.63

0.63

multiply each next year

   Severe

0.83

0.83

0.83

0.83

multiply each next year

Coverage

     

   Dose 1

50%

50%

50%

50%

 

   Dose 2

40%

40%

40%

40%

 

   20 years after introduction

80%

80%

80%

96%

for both doses

   Coverage improvement

linear

linear

linear

linear

 

Per-dose vaccine costs (2 doses)

    

   2009-2014

7.5

7.5

7.5

45

 

   2015 & beyond

4

4

4

45

Â